These early changes reflect the peptides activation of lipolytic pathways and increased fat oxidation, though visible physical changes are not yet apparent
The most common side effects of Wegovy include nausea, diarrhea, vomiting, constipation, abdominal (stomach) pain, headache, fatigue, dyspepsia (indigestion), dizziness, abdominal distension, eructation (belching), hypoglycemia (low blood sugar) in patients with diabetes, flatulence (gas buildup) and gastroesophageal reflux disease (heartburn)
These preclinical findings further implicate glucagon activation as the distinguishing factor between incretin receptor mono-, dual-, and triagonists, and they point to unimolecular polypharmacology as an efficient way to target several mechanisms causing obesity
Published Literature Context Published GHK and GHK-Cu literature spans copper-coordination chemistry and preclinical tissue-remodeling research models [2][3]